PMID- 26955045
OWN - NLM
STAT- MEDLINE
DCOM- 20170831
LR  - 20171119
IS  - 1558-2639 (Electronic)
IS  - 1536-1241 (Linking)
VI  - 15
IP  - 3
DP  - 2016 Apr
TI  - Modeling of Optimal Targeted Therapies Using Drug-Loaded Magnetic Nanoparticles 
      for Liver Cancer.
PG  - 265-74
LID - 10.1109/TNB.2016.2535380 [doi]
AB  - To enhance locoregional therapies for liver cancer treatment, we propose in this 
      study a mathematical model to optimize the transcatheter arterial delivery of 
      therapeutical agents. To maximize the effect of the treatment and minimize 
      adverse effects on the patient, different mathematical models of the tumor growth 
      are considered in this study to find the optimal number of the therapeutic 
      drug-loaded magnetic nanoparticles to be administered. Three types of therapy 
      models are considered, e.g., angiogenesis inhibition therapy, chemotherapy and 
      radiotherapy. We use state-dependent Riccati equations (SDRE) as an optimal 
      control methodology framework to the Hahnfeldt's tumor growth formulation. Based 
      on this, design optimal rules are derived for each therapy to reduce the growth 
      of a tumor through the administration of appropriate dose of antiangiogenic, 
      radio- and chemo-therapeutic agents. Simulation results demonstrate the validity 
      of the proposed optimal delivery approach, leading to reduced intervention time, 
      low drug administration rates and optimal targeted delivery.
FAU - Mellal, Lyes
AU  - Mellal L
FAU - Folio, David
AU  - Folio D
FAU - Belharet, Karim
AU  - Belharet K
FAU - Ferreira, Antoine
AU  - Ferreira A
LA  - eng
PT  - Journal Article
DEP - 20160229
PL  - United States
TA  - IEEE Trans Nanobioscience
JT  - IEEE transactions on nanobioscience
JID - 101152869
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Magnetite Nanoparticles)
RN  - 58784XQC3Y (Yttrium)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Computer Simulation
MH  - Doxorubicin/therapeutic use
MH  - Drug Delivery Systems/*methods
MH  - Humans
MH  - Liver Neoplasms/*drug therapy
MH  - Magnetic Resonance Spectroscopy/*therapeutic use
MH  - Magnetite Nanoparticles/*therapeutic use
MH  - *Models, Biological
MH  - Neovascularization, Pathologic
MH  - Yttrium/therapeutic use
EDAT- 2016/03/10 06:00
MHDA- 2017/09/01 06:00
CRDT- 2016/03/09 06:00
PHST- 2016/03/09 06:00 [entrez]
PHST- 2016/03/10 06:00 [pubmed]
PHST- 2017/09/01 06:00 [medline]
AID - 10.1109/TNB.2016.2535380 [doi]
PST - ppublish
SO  - IEEE Trans Nanobioscience. 2016 Apr;15(3):265-74. doi: 10.1109/TNB.2016.2535380. 
      Epub 2016 Feb 29.